Gary K. Lee - 11 Feb 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Heather Turner, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
11 Feb 2022
Net transactions value
$0
Form type
4
Filing time
14 Feb 2022, 19:59:36 UTC
Previous filing
04 Feb 2022
Next filing
28 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +800,000 $0.000000 800,000 11 Feb 2022 Common Stock 800,000 $6.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares shall vest on January 31, 2023, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.